A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Prior treatment

• Greater than 6 migraine days per month that are outside of the perimenstrual period in the 3 months prior to Screening
• A diagnosis of chronic migraine or a history of more than 14 headache days per month on average, in the 3 months prior to Screening

Other illness

• History of retinal migraine, basilar migraine or hemiplegic migraine
• Current diagnosis of schizophrenia, bipolar, or borderline personality disorder
• Other pain syndromes (eg, fibromyalgia, complex regional pain syndrome), or significant neurological disorders (other than migraine), or other medical conditions (including endocrine and gynecological eg, severe dysmenorrhea

• Participant has regular menstrual cycles ≥24 days and ≤34 days
• A minimum 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition
• A history of menstrual migraine attacks of at least 3 months
• Participant reported history of experiencing at least 1 migraine attack during the perimenstrual period in at least 2 out of 3 menstrual cycles immediately prior to screening.
• If the participant is receiving a permitted background continuous prophylactic migraine medication, the medication dose must be stable for at least 3 months prior to the Screening visit and, the dose is not expected to change during the course of the study